To explore whether the MGMT gene promoter methylation status affected the OS outcome of the combination of CW implantation and bevacizumab on glioblastoma, we compared our results to those of a multicenter retrospective study in Korean glioblastoma patients with total resection followed by Stupp’s regimen, in which the median OS was 28.6 months and 19.0 months in patients with methylated and unmethylated MGMT gene promoters, respectively [27]. This evidence concerns the gene MGMT and glioblastoma.